PURPOSE: Several trials have demonstrated the superiority of simultaneous chemoradiotherapy compared with radiation alone for patients with locally advanced head and neck cancers. However, the optimal regimen remains to be defined. This study assessed the safety and activity of combined carboplatin (C), paclitaxel (P), and twice-daily radiotherapy (RT) in a community based, multicenter, phase II trial. MATERIALS AND METHODS: Eligible patients (N = 52) had ECOG PS 0-2 and previously untreated, stage III or IV (M0), unresectable, squamous cell cancers of the head and neck. Treatment consisted of 6 weekly courses of C (AUC = 1), P (40 mg/m(2)/1-h) and twice-daily radiation (120 cGy BID; total dose of 6,960 cGy). Subsequently, patients with N2/N3 disease were permitted neck dissection. RESULTS: Median follow-up was 61 months. Sixty-seven percent (67%) of patients had stage IV (M0) disease at baseline. Fifty-five percent (55%) of treated patients experienced NCI Grade 3-4 dysphagia, stomatitis, or mucositis; 80% had > or = Grade 3 toxicity of any organ system. Median weight loss was 7.1 lbs; 35% of patients experienced 10% or more weight loss. Of 43 patients evaluable for response, responses were: 29 CR (67%), 7 PR (16%), 1 MR (2%), 4 SD (9%), and 2 PD (5%); the overall response rate (CR+PR) was 84%. For the entire cohort of 52 patients, the estimated overall survival at 36 months was 60%; progression-free survival was 50%. CONCLUSIONS: We conclude that weekly C + P and concurrent twice-daily hyperfractionated radiotherapy is tolerated and highly active in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck.
PURPOSE: Several trials have demonstrated the superiority of simultaneous chemoradiotherapy compared with radiation alone for patients with locally advanced head and neck cancers. However, the optimal regimen remains to be defined. This study assessed the safety and activity of combined carboplatin (C), paclitaxel (P), and twice-daily radiotherapy (RT) in a community based, multicenter, phase II trial. MATERIALS AND METHODS: Eligible patients (N = 52) had ECOG PS 0-2 and previously untreated, stage III or IV (M0), unresectable, squamous cell cancers of the head and neck. Treatment consisted of 6 weekly courses of C (AUC = 1), P (40 mg/m(2)/1-h) and twice-daily radiation (120 cGy BID; total dose of 6,960 cGy). Subsequently, patients with N2/N3 disease were permitted neck dissection. RESULTS: Median follow-up was 61 months. Sixty-seven percent (67%) of patients had stage IV (M0) disease at baseline. Fifty-five percent (55%) of treated patients experienced NCI Grade 3-4 dysphagia, stomatitis, or mucositis; 80% had > or = Grade 3 toxicity of any organ system. Median weight loss was 7.1 lbs; 35% of patients experienced 10% or more weight loss. Of 43 patients evaluable for response, responses were: 29 CR (67%), 7 PR (16%), 1 MR (2%), 4 SD (9%), and 2 PD (5%); the overall response rate (CR+PR) was 84%. For the entire cohort of 52 patients, the estimated overall survival at 36 months was 60%; progression-free survival was 50%. CONCLUSIONS: We conclude that weekly C + P and concurrent twice-daily hyperfractionated radiotherapy is tolerated and highly active in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck.
Authors: Pia Huguenin; Karl T Beer; Abdelkarim Allal; Kaspar Rufibach; Corinne Friedli; Jacques Bernard Davis; Bernhard Pestalozzi; Stephan Schmid; Armin Thöni; Mahmut Ozsahin; Jacques Bernier; Michael Töpfer; Roger Kann; Urs Richard Meier; Peter Thum; Sabine Bieri; Markus Notter; Norbert Lombriser; Christoph Glanzmann Journal: J Clin Oncol Date: 2004-11-08 Impact factor: 44.544
Authors: Dong M Shin; Bonnie S Glisson; Fadlo R Khuri; Scott M Lippman; Lawrence Ginsberg; Edward Diaz; Vassiliki Papadimitrakopoulou; Lei Feng; Marites Francisco; Adam Garden; Merrill S Kies; Jeffrey Myers; Gary Clayman; Waun Ki Hong Journal: Cancer Date: 2002-07-15 Impact factor: 6.860
Authors: Susanne M Arnold; William F Regine; Mansoor M Ahmed; Joseph Valentino; Paul Spring; Mahesh Kudrimoti; Daniel Kenady; Philip Desimone; Mohammed Mohiuddin Journal: Int J Radiat Oncol Biol Phys Date: 2004-04-01 Impact factor: 7.038
Authors: Anthony A Meluch; F Anthony Greco; James R Gray; Melodie Thomas; Valerie M Sutton; J Lucian Davis; Leonard A Kalman; Don W Shaffer; Kathleen Yost; David A Rinaldi; John D Hainsworth Journal: Cancer J Date: 2003 Jul-Aug Impact factor: 3.360
Authors: L Miszczyk; B Maciejewski; A Tukiendorf; G Woźniak; B Jochymek; A Gawryszuk; M Szweda Journal: Br J Radiol Date: 2014-07-16 Impact factor: 3.039
Authors: Irina Y Dobrosotskaya; Emily Bellile; Matthew E Spector; Bhavna Kumar; Felix Feng; Avraham Eisbruch; Gregory T Wolf; Mark E P Prince; Jeffrey S Moyer; Theodoros Teknos; Douglas B Chepeha; Heather M Walline; Jonathan B McHugh; Kitrina G Cordell; P Daniel Ward; Serena Byrd; Jessica H Maxwell; Susan Urba; Carol R Bradford; Thomas E Carey; Francis P Worden Journal: Head Neck Date: 2013-07-02 Impact factor: 3.147